Sign in →

Test Code IDH1 IDH1 Mutation (R132H) Immunostain, Technical Component Only


Advisory Information


This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.



Shipping Instructions


Attach the green pathology address label and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.



Specimen Required


Supplies: Immunostain Technical Only Envelope (T693)

Specimen Type: Tissue

Preferred: 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; sections 4-microns thick.

Acceptable: Formalin-fixed, paraffin-embedded (FFPE) tissue block


Secondary ID

70468

Useful For

Aids in the classification of gliomas

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
IHTOI IHC Initial, Tech Only No No
IHTOA IHC Additional, Tech Only No No

Method Name

Immunohistochemistry

Reporting Name

IDH1-R132H IHC, Tech Only

Specimen Type

TECHONLY

Specimen Stability Information

Specimen Type Temperature Time Special Container
TECHONLY Ambient (preferred)
  Refrigerated 

Reject Due To

Wet/frozen tissue Cytology smears Nonformalin fixed tissue Nonparaffin embedded tissue Noncharged slides ProbeOn slides Reject

Clinical Information

Antihuman isocitrate dehydrogenase 1 (IDH1) R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.

Interpretation

This test includes only technical performance of the stain (no pathologist interpretation is performed). Mayo Clinic cannot provide an interpretation of tech only stains outside the context of a pathology consultation. If an interpretation is needed, refer to PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case. All material associated with the case is required. Additional specific stains may be requested as part of the pathology consultation, and will be performed as necessary at the discretion of the Mayo pathologist.

 

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request. Contact 855-516-8404.

 

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Clinical Reference

1. Capper D, Weissert S, Balss J, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumorsBarin Pathol 2010 Jan;20(1):245-254
2. Capper D, Sahm F, Hartmann C, et al: Application of mutant IDH1 antibody to differentiate diffuse glioma form nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010 Aug;34(8):1199-1204
3. Camelo-Piragua S, Jansen M, Ganguly A, et al: Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma form astrocytosis. Acta Neuropathol 2010 Apr;119(4):509-511
4. Andrulis M, Capper D, Luft T, et at: Detection of isocitrate dehydrogenase 1 mutation in R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leuk Res 2010 Aug;34(8):1091-1093
5. Dunbar E, Yachnis AT: Glioma diagnosis: immunohistochemistry and beyond. Adv Anat Pathol 2010 May;17(3):187-201
6. Capper D, Zentgraf H, Balss J, et al: Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathpol 2009 Nov;118(5):599-601

Day(s) and Time(s) Performed

Monday through Friday

Analytic Time

1 day

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

88342-TC, primary

88341-TC, if additional IHC

LOINC Code Information

Test ID Test Order Name Order LOINC Value
IDH1 IDH1-R132H IHC, Tech Only Order only;no result

 

Result ID Test Result Name Result LOINC Value
70780 IDH1-R132H IHC, Tech Only Bill only; no result

Forms

If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.

Testing Algorithm

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).